BioDelivery Sciences International (NASDAQ:BDSI) and Moleculin Biotech (NASDAQ:MBRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, risk, dividends and earnings.
Profitability
This table compares BioDelivery Sciences International and Moleculin Biotech's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
---|
BioDelivery Sciences International | 10.16% | 25.04% | 9.89% |
Moleculin Biotech | N/A | -113.25% | -63.20% |
Volatility and Risk
BioDelivery Sciences International has a beta of 0.72, indicating that its share price is 28% less volatile than the S&P 500. Comparatively, Moleculin Biotech has a beta of 2.11, indicating that its share price is 111% more volatile than the S&P 500.
Insider & Institutional Ownership
67.4% of BioDelivery Sciences International shares are held by institutional investors. Comparatively, 4.8% of Moleculin Biotech shares are held by institutional investors. 8.6% of BioDelivery Sciences International shares are held by company insiders. Comparatively, 8.3% of Moleculin Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Earnings & Valuation
This table compares BioDelivery Sciences International and Moleculin Biotech's top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
---|
BioDelivery Sciences International | $111.39 million | 3.59 | $-15,310,000.00 | $0.10 | 39.60 |
Moleculin Biotech | N/A | N/A | $-13,200,000.00 | ($0.32) | -11.63 |
Moleculin Biotech has lower revenue, but higher earnings than BioDelivery Sciences International. Moleculin Biotech is trading at a lower price-to-earnings ratio than BioDelivery Sciences International, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current ratings and recommmendations for BioDelivery Sciences International and Moleculin Biotech, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
---|
BioDelivery Sciences International | 0 | 1 | 4 | 0 | 2.80 |
Moleculin Biotech | 0 | 0 | 2 | 0 | 3.00 |
BioDelivery Sciences International presently has a consensus target price of $8.45, indicating a potential upside of 113.38%. Moleculin Biotech has a consensus target price of $15.00, indicating a potential upside of 303.23%. Given Moleculin Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Moleculin Biotech is more favorable than BioDelivery Sciences International.
Summary
BioDelivery Sciences International beats Moleculin Biotech on 9 of the 13 factors compared between the two stocks.